All In Biotech

Drug Trial Radar · NCT07565103

Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

426

Planned (sponsor's estimate)

Start

Jun 25, 2026

Primary completion

Aug 15, 2028

Study completion Aug 15, 2028

Sponsor

Lead sponsor
Senju USA, Inc.Industry
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.

Conditions

  • Bacterial Conjunctivitis

Interventions

  • SUM-191Drug

    Part 1 (SAD): SUM-191 is administrated a single dose topically. Part 2 (MAD): SUM-191 is administrated TID topically for 6 days. Part 3: SUM-191 is administrated TID topically for 6 days.

  • PlaceboDrug

    Part 1 (SAD): Placebo is administrated a single dose topically. Part 2 (MAD): Placebo is administrated TID topically for 6 days. Part 3: Placebo is administrated TID topically for 6 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident of Adverse Events (AEs) (Part 1 and Part 2)Time frame: Part 1: From Day 1 to Day 7 Part 2: From Day 1 to Day 14
  2. Severity of Adverse Events (AEs) (Part 1 and Part 2)Time frame: Part 1: From Day 1 to Day 7 Part 2: From Day 1 to Day 14
  3. Clinical cure (Part 3)Time frame: Day 7 or 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Segal Drug Trials Inc

    Delray Beach, Florida · Recruiting

  • Austin Clinical Research Unit

    Austin, Texas · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.